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an Natriuretic
eptides Help Identify
eart Failure Patients for
hom Statins Are Beneficial?*
ori B. Daniels, MD, MAS,†
lizabeth Barrett-Connor, MD‡
an Diego, California
ne of the great success stories in cardiology is the ability of
tatins to improve the prognosis in patients at risk of a first
r subsequent cardiovascular event. This benefit has been
hown across a wide spectrum of patient profiles. The
fficacy of statin therapy has been challenged only in
igh-risk patients such as those on dialysis (1,2), older
atients with systolic heart failure (3), and patients with
hronic heart failure of any cause (4).
See page 1850
Large retrospective studies, observational studies, and stud-
es using surrogate end points had many believing that the
eneficial effects of statins would extend to heart failure
atients. This optimism was curtailed with publication of the
ORONA (Controlled Rosuvastatin Multinational Trial in
eart Failure) study, the first multicenter, randomized,
ouble-blind, placebo-controlled study assessing the effect of
tatins in congestive heart failure patients (3). This clinical trial
ncluded 5,011 patients who were at least 60 years of age, with
ew York Heart Association functional class II or greater
schemic heart failure and reduced left ventricular ejection
raction; participants were randomized to receive either 10-mg
osuvastatin daily or placebo and were followed for a median of
.7 years. Although rosuvastatin decreased low-density li-
oprotein cholesterol, it conferred no significant benefit on the
rimary composite outcome (death from cardiovascular dis-
ase, nonfatal myocardial infarction, or nonfatal stroke) or on
he secondary individual outcomes of death, any coronary
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ave received research support from Biosite, Inc., and Roche Diagnostics, Inc.vent, and cardiovascular death. As elegantly reviewed by
asoudi (5), these negative results could have been due to a
ack of benefit of statins in ischemic heart failure, a
osuvastatin-specific shortcoming, or the advanced age and
omorbidities of the population. Rosuvastatin did decrease
ospitalizations (for worsening heart failure, p  0.01; for
ardiovascular disease, p  0.001; and for all-cause hospital-
zations, p  0.007).
Subsequently, the GISSI-HF (Gruppo Italiano per lo Stu-
io della Sopravivenza nell’Insufficienza Cardiaca Heart Fail-
re), a randomized trial of 4,574 heart failure patients followed
or a median of 3.9 years, extended the findings of CORONA
o patients with chronic heart failure of any cause and irrespec-
ive of left ventricular ejection fraction. In this trial, rosuvastatin
id not significantly reduce the primary outcome of death or of
eath or cardiovascular hospitalization (4).
Patients with ischemic heart disease typically derive
ubstantial benefit from statin therapy (6). At some point
fter the development of heart failure, however, cardiac
rotection seems to wane, and patients reach a point where
heir cardiovascular disease is too advanced to modify with
tatin therapy or competing risks negate benefit from statin
reatment. It would be clinically useful to hone in on the
ransition point along the continuum of ischemic heart
isease and heart failure severity where statins are no longer
ffective at improving most outcomes.
Natriuretic peptides are hormones that are secreted by
ardiomyocytes in response to increased ventricular stretch (7).
oth B-type natriuretic peptide (BNP) and its N-terminal
recursor (NT-proBNP) have significant prognostic value in
atients with ischemic heart disease and heart failure (8–10).
herefore, natriuretic peptides should be good candidates for
ttempting to distinguish lower-risk heart failure patients who
ay benefit from statins from higher-risk heart failure patients
n whom statin therapy is likely to be futile.
This possibility was retrospectively evaluated using data
rom the Heart Protection Study in which 20,536 subjects at
igh risk of vascular disease were randomly assigned to
ither simvastatin 40 mg/day or placebo (11). As expected,
aseline NT-proBNP levels were strongly and indepen-
ently predictive of future vascular events. Higher baseline
T-proBNP levels also were associated with a smaller, but
till highly statistically significant, relative risk reduction in
vents with statin therapy (despite similar absolute reduc-
ions in low-density lipoprotein cholesterol). However,
ecause participants with higher NT-proBNP levels had a
reater absolute risk of events, the absolute benefits of statin
herapy were similar at all levels of NT-proBNP. Because
he presence of heart failure was not recorded at baseline, no
irect conclusions could be drawn about the utility of statins
n patients with and without heart failure.
In this issue of the Journal, Cleland et al. (12) report a post
oc analysis of 3,664 patients from the CORONA study in
hom NT-proBNP levels were measured before randomiza-ion to either rosuvastatin or placebo. Unlike the Heart
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ymptomatic heart failure due to ischemic heart disease with
educed left ventricular ejection fraction. Although rosuvastatin
herapy failed to significantly improve primary outcomes over-
ll (3), the investigators found that after stratifying by tertile of
T-proBNP, patients in the lowest tertile (NT-proBNP
868 pg/ml) did benefit from rosuvastatin therapy, with a
ignificant reduction in the primary end point (cardiovascular
ortality, nonfatal myocardial infarction, or nonfatal stroke) as
ell as in 2 pre-specified secondary end points: the composite
oronary end point and hospitalizations.
As in the Heart Protection Study, low-density lipoprotein
holesterol was lowered similarly in each tertile of NT-
roBNP and did not explain the lack of benefit from rosuvas-
atin in the upper 2 tertiles. Discontinuation of randomized
reatment did increase with increasing values of NT-proBNP,
ut probably not enough to account for the difference.
In addition to discovering a subgroup of ischemic heart failure
atients in whom rosuvastatin was beneficial, the investigators also
onfirmed the strong prognostic value of NT-proBNP, which was
stronger predictor of each pre-specified outcome than any other
ariable measured in this cohort. That NT-proBNP is so prog-
ostically powerful lends credence to the hypothesis that lower-
isk heart failure patients who may still benefit from statin therapy
an be identified and that natriuretic peptides may be better suited
o this task than any other readily available clinical parameter.
owever, as plausible as this hypothesis seems, caution must be
xercised in interpreting any post hoc subgroup analysis, especially
hen the analysis is designed to look for benefit in a subset of
verall null results (13). It seems that the use of tertiles for
tratification of NT-proBNP levels was not pre-specified, and it is
nclear how robust these data would be to other cut points.
alidation in other studies and prospective trials using natriuretic
eptides with pre-specified cut points to guide statin administra-
ion will be essential to fully explore this paradigm.
Other factors that could influence the generalizability of
hese results pertain to the particulars of the population
tudied in CORONA. Natriuretic peptide levels are known
o rise with increasing age, and the mean age in CORONA
as 73 years, with approximately 40% of subjects older than
he age of 75. This was also a sick population: in addition to
mean left ventricular ejection fraction of approximately
0%, 25% of the patients in this study had NT-proBNP
evels 423 pg/ml. Nonischemic heart failure patients were
ot studied, and whether natriuretic peptides will be useful
o guide statin therapy in them remains unknown.
In addition to these cohort-specific caveats, characteris-
ics of natriuretic peptide levels themselves will influence
ow these results translate into clinical practice. There is
ignificant intraindividual variability in natriuretic peptide
evels that may preclude defining any single cut point as the
uide for statin administration in heart failure patients;
ore likely there will be a cut point with a surrounding
gray zone” where clinical judgment will, as always, play a
ritical role. Finally, if natriuretic peptides are used to guide
tatin use in lower-risk heart failure patients, what will be
K
phe correct approach when a heart failure patient on statin
herapy decompensates? In patients with more advanced
eart failure who stand to garner less benefit from statin
herapy, the potential risks of statin use plus the associated
ost of continued therapy might tilt the risk-benefit ratio
oward discontinuation of statin therapy.
How should these results affect our clinical decision
aking? Clinical practice guidelines recommend that statins
e prescribed to patients with ischemic heart disease (14),
ut do not make heart failure a consideration. If these
esults are confirmed in other studies, natriuretic peptide
evels may have a new application in guiding statin decisions
or heart failure patients.
eprint requests and correspondence: Dr. Lori B. Daniels,
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